Editors are advised that a high-resolution photo is available to accompany the news release, NYTU092, FDA Approves Nexavar(R) for Treatment of Patients with Advanced Kidney Cancer, issued yesterday by Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. Caption: Nexavar(R) (sorafenib) tablets received U.S. FDA approval for the treatment of patients with advanced kidney cancer. Nexavar is an oral anti-cancer drug with a recommended dose of 400 mg (two 200 mg pills) taken twice daily. For Nexavar prescribing information, visit http://www.nexavar.com/ or call 1.866.NEXAVAR (1.866.639.2827). (PRNewsFoto) Members of the media may download the photo at no charge from the following online archives: -- NewsCom: http://www.newscom.com/cgi-bin/prnh/20051221/NYTU092 -- AP Archive Topic Gallery: http://photoarchive.ap.org/ This photo is also available via the AP PhotoExpress Network, as PRN4. For more information on the photo, or on gaining access to the archives, media may contact the PR Newswire Photo Desk at +1-888-776-6555 or +1-212-782-2840. PRNewswire -- Dec. 21 http://www.newscom.com/cgi-bin/prnh/20051221/NYTU092 http://photoarchive.ap.org/ DATASOURCE: Bayer Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.

Copyright